Immunic will continue developing its multiple sclerosis (MS) drug, vidofludimus calcium (IMU-838), despite a Phase II trial ...

Shares of TransCode Therapeutics Inc surged nearly 39% on Thursday after the company announced encouraging progress in its ...

According to CEO Daniel Vitt, clinical and disability-related outcomes are more relevant than brain volume change for drug ...

Shares of Arvinas fell after the biotechnology company ended plans for two Phase 3 trials as part of its collaboration with Pfizer, and said that it would cut about a third of its workforce. The stock ...

Approval is based on results from the Phase III ASCEND trial, in which patients using the powder achieved freedom from pain ...

A phase 1 trial has initiated and is investigating treatment with ziftomenib plus Gleevec in advanced GIST following ...

The medication, called lorundrostat, was found to significantly lower blood pressure in a recent clinical trial. The findings ...

The EMA has recommended extensions to the marketing authorizations for Adcetris, used to treat Hodgkin lymphoma, and ...

The FDA approved dihydroergotamine (DHE) nasal powder (Atzumi) 5.2 mg to treat acute migraine with or without aura in adults, ...

(Reuters) -Amgen on Thursday said its first-quarter profit rose 24%, handily exceeding Wall Street expectations, as product ...

Verona Pharma’s Ohtuvayre generated $71.3M in Q1'25 sales, signaling blockbuster potential. Read more on VRNA’s upcoming ...

A trial shows that semaglutide stops fat accumulation and liver fibrosis in a disease associated with metabolic dysfunction ...